Ratings by Raymond James (Tiago Fauth)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/9/2026 | Quince Therapeutics Inc. | QNCX | New Coverage | Outperform (N/A) |
29.36 (31.73) |
8.07% | Details | |
| 10/2/2026 | Avalyn Pharma | AVLN | New Coverage | Outperform (N/A) |
27.42 (23.66) |
-13.71% | Details | |
| 9/25/2026 | Seaport Therapeutics | SPTX | New Coverage | Strong Buy (N/A) |
21.12 (17.83) |
-15.58% | Details | |
| 9/22/2026 | Rapport Therapeutics | RAPP | Maintain | Strong Buy (N/A) |
|
Details | ||
| 9/22/2026 | Tonix Pharma | TNXP | Maintain | Strong Buy (N/A) |
|
Details | ||
| 9/8/2026 | Ionis Pharmaceuticals | IONS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/17/2026 | Rapport Therapeutics | RAPP | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/17/2026 | Praxis Precision Medicines Inc. | PRAX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/13/2026 | Polaryx Therapeutics | PLYX | New Coverage | Strong Buy (N/A) |
2.23 (1.88) |
-15.7% | Details | |
| 8/10/2026 | Tonix Pharma | TNXP | Maintain | Strong Buy (N/A) |
|
Details | ||
| 7/27/2026 | MapLight Therapeutics | MPLT | Maintain | Strong Buy (N/A) |
|
Details | ||
| 6/24/2026 | Tonix Pharma | TNXP | New Coverage | Strong Buy (N/A) |
11.96 (6.04) |
-49.5% | Details | |
| 6/24/2026 | MapLight Therapeutics | MPLT | New Coverage | Strong Buy (N/A) |
28.64 (7.70) |
-73.11% | Details | |
| 5/7/2026 | Rapport Therapeutics | RAPP | Maintain | Strong Buy (N/A) |
|
Details | ||
| 4/9/2026 | PTC Therapeutics | PTCT | New Coverage | Outperform (N/A) |
71.26 (59.24) |
-16.87% | Details | |
| 4/9/2026 | Jazz Pharmaceuticals | JAZZ | New Coverage | Outperform (N/A) |
195.93 (210.23) |
7.3% | Details | |
| 4/9/2026 | Praxis Precision Medicines Inc. | PRAX | New Coverage | Strong Buy (N/A) |
320.22 (241.76) |
-24.5% | Details | |
| 4/9/2026 | Ionis Pharmaceuticals | IONS | New Coverage | Outperform (N/A) |
74.98 (42.94) |
-42.73% | Details | |
| 4/9/2026 | Insmed | INSM | New Coverage | Outperform (N/A) |
160.18 (96.27) |
-39.9% | Details | |
| 4/9/2026 | Rapport Therapeutics | RAPP | New Coverage | Strong Buy (N/A) |
33.69 (27.57) |
-18.17% | Details | |
| 4/9/2026 | United Therapeutics Corp. | UTHR | New Coverage | Outperform (N/A) |
581.69 (533.12) |
-8.35% | Details |
